Breaking AI & Tech News Analyzed

UK lawmakers have urged the government to reconsider its £330m contract with Palantir, a technology company known for its work with Donald Trump's ICE immigration agency and the Israeli military. The contract is for the NHS federated data platform (FDP), which has sparked concerns over data privacy and the company's ties to Peter Thiel, a Trump-supporting tech billionaire.MPs, including Luke Taylor and Samantha Niblett, have described the deal as 'shameful' and 'dreadful', questioning whether Palantir can be trusted with the health records of tens of millions of British citizens. The government has confirmed it will review the contract in spring 2027, when a break clause is due.Despite £210m already being spent on the contract, the government has faced rising pressure from doctors, MPs, and the public to reconsider its deal with Palantir. The company has countered that its software has helped deliver 110,000 additional operations and reduced discharge delays.The FDP has been one of the most controversial contracts in the UK public sector, with internal documents revealing health bosses' concerns over 'negative sentiment' about the system. The government has said 137 NHS trusts have signed up to use the Palantir-powered system, but there are concerns that usage is 'shallow'.

For the first time, thousands of cancer patients from Black and minority ethnic backgrounds will benefit from an enhanced genetic test offered by the NHS. The new screening expands the panel of DPYD gene variants from four to five, directly addressing a long‑standing bias that left non‑white patients vulnerable to dangerous chemotherapy side‑effects. In England, patients slated for chemotherapy undergo a genetic check that can guide dose adjustments and mitigate adverse reactions such as mouth sores, hair loss, nausea, fatigue, and, in severe cases, death. Up to 40% of the 38,000 individuals receiving fluoropyrimidine‑based chemotherapy each year experience a harmful drug reaction. Previously, the test only targeted four DPYD variants common in people of European descent, meaning many Black patients received inaccurate “all‑clear” results. The addition of a fifth variant—more prevalent among African, Caribbean and other minority groups—means clinicians can now identify patients at risk who were previously missed. Since its rollout at Manchester University NHS Foundation Trust last September, three minority‑ethnic patients have had their initial chemotherapy doses adjusted, lowering their chance of a potentially fatal reaction. Dr Veline L’Esperance, senior clinical adviser at the NHS Race and Health Observatory, called the change “tangible results for patients who have historically been left behind.” She emphasized that the update shifts the discussion on ethnic health inequality from rhetoric to actionable care. Prof Habib Naqvi, chief executive of the NHS Race and Health Observatory, described the development as a “groundbreaking outcome” for chemotherapy safety, while noting that ethnic minorities remain under‑represented in genomic research and biobanks. He warned that broader inclusion is essential for the promised benefits of precision medicine to reach all communities. Prof Dame Sue Hill, chief scientific officer for NHS England, highlighted the significance of discovering the fifth variant: “Personalising chemotherapy based on genetics can save lives and reduce harmful side‑effects, especially for patients of African ancestry.” She added that the North West NHS Genomic Medicine Service has already demonstrated the practical impact of this approach. These steps come amid broader evidence that minority patients in the UK face longer diagnostic waits, more GP visits before a cancer diagnosis, and lower perceived support during treatment. The expanded DPYD test represents a concrete effort to close those gaps and ensure equitable, science‑driven care for all cancer patients.

Scientists at London's Institute of Cancer Research and the RCSI University of Medicine and Health Sciences in Dublin have announced a new AI-driven approach to identify how patients with advanced bowel cancer will respond to bevacizumab, a drug recently introduced by the NHS. The method uses PhenMap, an AI tool that integrates complex data on the genetic makeup of tumors, allowing researchers to track patterns of how different patients react to the drug. This development aims to spare potentially thousands of patients from being given drugs that would be ineffective in fighting their cancers. In the UK alone, nearly 10,000 cases of advanced bowel cancer are identified every year, with young adults seeing a particular rise in diagnoses. Bowel cancer has the second-highest mortality rate of any cancer, behind only lung cancer. While survival rates can be as high as 98% when caught early, the five-year survival rate for advanced bowel cancer can be as low as 10%. The study tracked 117 European bowel cancer patients who had been treated with chemotherapy and bevacizumab. Researchers identified a group of patients who all had the same gene mutation and were at a high risk of having negative reactions. The scientists behind the tests now hope to expand the number of patient samples and see if the results can be used in treatments for other types of cancer. Anguraj Sadanandam, a professor in stratification and precision medicine at the ICR, said: “Once bowel cancer spreads to other parts of the body, there are very few treatment options available for patients. It is therefore positive that patients can now access the targeted drug bevacizumab on the NHS. However, we know that the majority of patients won’t benefit from the drug, meaning thousands of people in England could be facing unpleasant side effects unnecessarily.” Sadanandam added that while the findings were encouraging, the tool would need to be tested on a larger cohort to be validated. “In future, I hope this approach will lead to a test that can be used by clinicians, to ensure patients receive personalised care that has the highest chance of working against their cancer.”

A 47‑year‑old woman who had endured three life‑threatening autoimmune diseases for more than a decade is now living a near‑normal life after an experimental CAR‑T cell therapy reset her immune system at University Hospital Erlangen in Germany.Before the procedure she had exhausted nine different treatments with no lasting benefit, relying on daily blood transfusions and continuous anticoagulation to manage her illnesses.Within weeks of the infusion, doctors observed rapid improvement in all three conditions—a world‑first outcome. She has remained in treatment‑free remission for 14 months and has largely returned to everyday activities.Prof Fabian Müller, who led the team, called the speed and depth of the response “remarkable” and said the therapy “significantly improved her quality of life.” He emphasized that clinical trials are required to determine how durable the effect is and whether it can help other autoimmune patients.The patient suffered from three distinct disorders: autoimmune haemolytic anaemia (AIHA), where rogue immune cells destroy red blood cells; immune thrombocytopenia (ITP), which depletes platelets and raises bleeding risk; and antiphospholipid syndrome (APS), which promotes dangerous blood clots. All three stem from malfunctioning B‑cells.With no conventional options left, doctors turned to CAR‑T therapy, a technique that has revolutionised treatment for certain cancers. They harvested her white‑blood cells, isolated the T‑cells, engineered them to recognise the CD19 protein on B‑cells, and reinfused the modified cells.The engineered T‑cells swiftly eliminated the pathogenic B‑cells. She received her last blood transfusion a week after treatment and was able to perform routine tasks within two weeks. Follow‑up tests showed a reconstituted, healthy B‑cell population, suggesting an immune reset. The findings were published in the journal Med.She still exhibits a mildly low white‑cell count and slightly elevated liver enzymes, which researchers attribute to the cumulative impact of prior therapies rather than the CAR‑T product.Rheumatology expert Prof Ben Parker of Manchester University NHS Foundation Trust described the case as encouraging, noting that “the prolonged response off normal therapy suggests there has been an immune reset.” However, he warned that case reports alone cannot confirm efficacy and highlighted ongoing trials for lupus, myositis, multiple sclerosis, systemic sclerosis, vasculitis, and other autoimmune conditions.

Health‑service workers have voiced strong unease after it emerged that engineers from the controversial US tech firm Palantir were issued NHS.net email accounts. Those accounts unlock a directory containing contact details for as many as 1.5 million NHS staff members, as well as access to SharePoint file‑sharing and Microsoft Teams groups used by the service. Palantir’s engineers are supporting the rollout of the Federated Data Platform (FDP), a £300 million contract awarded in 2023 to link patient records across disparate NHS systems. The government touts FDP as a cornerstone of its plan to "reinvent the NHS" by moving from analogue to digital, promising faster diagnoses, better appointment allocation and more personalised treatment. While the use of NHS email accounts by external suppliers is not unprecedented, Palantir’s reputation for AI‑driven surveillance and military‑grade technology has amplified staff, patient and human‑rights concerns. Rory Gibson, a resident doctor, warned that his personal contact details should not be accessible to a company that also works on drone‑strike systems. The Guardian has identified at least six Palantir engineers who have been given NHS.net credentials. In response, a Palantir spokesperson argued that such access is "normal practice for government suppliers" and cited official guidance that government systems are more secure than external alternatives. Palantir claims its software has already yielded measurable benefits: 110,000 additional operations, a 15.3% reduction in discharge delays and a 6.8% rise in cancer diagnoses within 28 days of referral. The company stresses that it merely provides software, with data usage remaining under NHS control and subject to strict contractual confidentiality. David Rowland, director of the Centre for Health and the Public Interest, acknowledged that granting NHS email addresses may not breach rules but highlighted the "deep ethical concerns" that Palantir’s profit‑driven model clashes with NHS values. He called for a comprehensive review of which private firms receive public‑sector funding. Some NHS staff reported being placed in virtual Teams meetings with Palantir personnel who joined using NHS credentials, without any disclosure of their employer – a practice that further eroded trust. Under the NHSmail access policy, "independent sector organisations" delivering health and social‑care services nationally may use NHSmail. An unrestricted NHS.net account can reveal staff roles, locations, workplace details and even grant access to commercial "Blue Light" discounts. Palantir’s technology is already deployed by UK police forces and the Ministry of Defence, prompting critics to warn that its "drag‑and‑drop" interoperability could facilitate state overreach, including a potential British analogue of the US Immigration and Customs Enforcement agency. The firm’s founders include US businessman and former Trump supporter Peter Thiel and CEO Alex Karp, both known for advocating aggressive surveillance tools. Its UK arm is led by Louis Mosley, grandson of historic British fascist leader Oswald Mosley. An NHS spokesperson reiterated that all suppliers, including Palantir, operate strictly under NHS instruction, with data access governed by robust contractual confidentiality obligations.

Palantir’s claim that opposition to its NHS contract is driven by ideology was rebuked by Chi Onwurah, the Labour MP who chairs Parliament’s science, innovation and technology select committee. Onwurah said it is appropriate for ministers to explore a break‑clause option in the deal, underscoring the seriousness of the concerns raised. Louis Mosley, Palantir’s UK executive vice‑chair, had urged the government not to succumb to “ideologically motivated campaigners” as officials weighed a way out of a £330 million contract to deliver the Federated Data Platform (FDP) for NHS England. Ministers have now asked for advice on triggering the contract’s break clause amid growing scrutiny of Palantir’s expanding role in the public sector. The FDP is an AI‑enabled platform designed to integrate disparate health information across the NHS. Palantir already holds contracts with the Ministry of Defence, several police forces and the UK’s financial watchdog, the FCA. Onwurah’s cross‑party committee is set to publish its report in the coming weeks, covering the digital reorganisation of government services and the role of AI after a series of hearings that included experts, NHS leaders and representatives from companies such as Palantir. She identified three core issues: the manner in which the contract was awarded, the handling of patient data and the resulting trust deficit within the NHS, and the involvement of Peter Mandelson through his firm Global Counsel. “These are not fringe ideological concerns,” Onwurah told the Guardian. “They relate to contract transparency, vendor lock‑in, value for money and data security – matters that should concern everyone pushing the NHS towards digital transformation.” She added that the NHS’s post‑COVID fatigue and austerity‑driven burnout make any additional trust‑related resentment a significant barrier to progress. Onwurah noted that Palantir secured the contract after providing services to the NHS at a nominal cost – a tactic often used by large tech firms to position themselves as the most attractive government supplier. “It is right for the government to explore all options, including breaking the contract, given ongoing concerns about FDP uptake while Palantir remains at the helm,” she said. Liberal Democrat MP Martin Wrigley, also on the committee, urged the government to commission a new consortium of UK‑based tech experts to build a home‑grown NHS platform. During a previous committee appearance, Mosley accused British doctors of placing “ideology over patient interest” after they challenged the data‑processing contract. Speaking to the Times, Mosley warned that removing Palantir could jeopardise patient care and stall solutions to the NHS’s biggest challenges, arguing that the campaign against the firm would do more harm than good.

Palantir’s senior UK representative has warned ministers against yielding to ideologically motivated campaigners as they explore the possibility of terminating a £330 million NHS contract for the company’s Federated Data Platform (FDP).The FDP, an AI‑enabled system intended to unify patient information across the health service, is part of a broader portfolio that includes contracts with the Ministry of Defence, several police forces and the UK’s financial regulator.Louis Mosley, executive vice‑chair of Palantir UK, told The Times that abandoning the deal would jeopardise patient care and hinder progress on the NHS’s most pressing challenges. He highlighted that the platform is projected to generate £150 million in benefits by the end of the decade, delivering a £5 return for every pound spent.According to the Financial Times, senior officials have begun informal discussions about activating a break clause that would allow the FDP’s operation to be transferred to an alternative provider once the system becomes fully operational next year.Palantir, a US‑based data‑analytics firm with ties to the Israeli and US militaries and former U.S. Immigration and Customs Enforcement contracts, has faced sustained opposition from the British Medical Association, which has long criticised the use of its technology in patient‑care settings.Health officials acknowledge the reputational risk, noting that the controversy now extends beyond traditional Labour‑left and Green Party critics. A Department of Health and Social Care spokesperson emphasised that the FDP is designed to improve care coordination, accelerate cancer diagnoses and increase treatment capacity, while maintaining strict data‑security safeguards.Health Secretary Wes Streeting, speaking on the Guardian Politics Weekly podcast, recognised public unease about Palantir’s political affiliations, referencing founder Peter Thiel’s right‑wing connections. He reassured listeners that Palantir does not have direct access to patient data, stating, "The platform is operated by us; Palantir never sees the data."Adoption of Palantir’s technology within the NHS has risen from 118 to 151 organisations since June, though it remains short of the government’s target of 240 organisations by year‑end. Labour backbencher Clive Lewis noted that the issue is becoming a visible concern for voters, reflecting broader anxieties about AI and foreign‑owned infrastructure in critical public services.

The tragic case of Oliver Robinson, a 34-year-old who took his own life in November 2023, has sparked a campaign for stricter controls on private cannabis clinics in the UK. An inquest concluded that Robinson's prescription for medicinal cannabis, issued by Curaleaf Clinic, probably contributed to his death and acted as an obstacle to him receiving proper psychiatric and addiction care. Robinson had been struggling with depression and addiction, and had been treated at the Priory, a private mental health facility. He was initially prescribed medicinal cannabis in May 2022, which initially provided relief but ultimately worsened his condition. The coroner's report highlighted several failings in his care, including the use of an out-of-date GP summary care record and incomplete information in prescribing decisions. Alexander Robinson, Oliver's brother, is now advocating for tighter regulation of private cannabis clinics, including a ban on prescribing to patients with serious mental illness and greater oversight of the rapidly expanding industry. He believes that the current safeguards are not strong enough to protect vulnerable psychiatric patients. The UK government reported about 5,000 NHS prescriptions for licensed cannabis-based medicinal products in 2023, while freedom of information data showed that 659,293 unlicensed cannabis products were privately prescribed in 2024, more than double the number issued in 2023. Critics argue that there is limited evidence that cannabis is an effective treatment for depression and other common mental health conditions. Dr. Pavan Chahl, an expert psychiatrist, told Oliver's inquest that medicinal cannabis should not have been prescribed to someone with a history of severe psychiatric disorder, citing a lack of evidence for efficacy in depression and the risk of worsening symptoms. In response to the campaign, Curaleaf Clinic stated that it would engage constructively with any review or consultation aimed at strengthening patient safety across the sector.

The UK's National Health Service (NHS) is facing potential medicine shortages due to supply chain disruptions, with the head of NHS England, Jim Mackey, warning that some medicines could run out in weeks or even days. Mackey cited the country's reliance on imports, with 75% of medicines coming from abroad, as a major concern.Mackey revealed that a team is in place to focus on identifying potential risks in the supply chain, and that the NHS is working to mitigate the impact of any disruptions. He stated that the NHS generally has enough medicine to last a few weeks, but that some products may only have days' worth of supply.The concerns about medicine shortages come amid the ongoing conflict in the Middle East, which has raised worries about cost implications and supply disruption. Experts have noted that pharmacies are seeing disturbing spikes in prices, which can be an early indicator of challenges.The UK government has stated that there are currently no reported medicine shortages as a result of the conflict, but that they are monitoring the situation closely and have established processes in place to manage disruption across the health and social care sector.